Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1Breast 1

Conditions

Stomach Neoplasms 1Cholangiocarcinoma 1Breast Neoplasms 1

Interventions

pembrolizumab 11Fluorouracil 10Oxaliplatin 8Nivolumab 7Leucovorin 6Cisplatin 6Capecitabine 6Sorafenib 5Ipilimumab 5Cetuximab 5Bevacizumab 5Irinotecan 4trifluridine tipiracil drug combination 3trastuzumab deruxtecan 3durvalumab 3cabozantinib 3Trastuzumab 3Paclitaxel 3zolbetuximab 2trametinib 2sodium thiosulfate 2selpercatinib 2relatlimab 2lenvatinib 2larotrectinib 2encorafenib 2dabrafenib 2binimetinib 2X-Rays 2Specimen Handling 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has announcements × futibatinib × Gastrointestinal × Clear all
NCT02052778 2025-03-27

A Study of TAS-120 in Patients With Advanced Solid Tumors

Taiho Oncology, Inc.

Phase 1/2 Completed
407 enrolled 45 charts 1 FDA
BreastGastrointestinal

Breast Neoplasms, Stomach Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡